Health Dictionary Find a Doctor

Seizure pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]

Overview

Normally, seizures do not occur because the membrane stability of neurons is maintained, and the discharges that lead to seizures are prevented from transferring. In a normal brain, some circumstances can provoke seizures, such as: hyponatremia, drug withdrawal, and hypoglycemia. Abnormalities in different parts of the nervous system may cause seizure, such as: brain regions, cells, ions, networks, and receptors. The imbalance of excessive excitation and reduced inhibition can cause seizures and is also responsible for prolonging it if the imbalance persists. Glutamate is the most common excitatory neurotransmitter and acts on the N-methyl-D-aspartate (NMDA) receptor. However, NMDA antagonist drugs have not been clinically successful. Gamma-aminobutyric acid (GABA) is the most common inhibition neurotransmitter. GABA inhibits excess excitation of the neurons by activating the GABAA receptor. Increasing the inhibition of GABA (even if the inhibition is not damaged) may be helpful in a seizure, since it may overwhelm the excess excitation of the seizure. Examples of GABA-enhancing drugs are benzodiazepines, barbiturates, propofol, and some anesthetics. However, these drugs are not suitable for long term therapy since patients usually become tolerant to their effect.

Pathophysiology

Normally, seizures do not occur because the membrane stability of neurons is maintained, and the discharges that lead to seizures are prevented from transferring.[1]

In a normal brain, some circumstances can provoke seizures, such as:[1]

Abnormalities in different parts of the nervous system may cause seizure, such as:[1]

For example:

Pathophysiology of generalized tonic-clonic seizures

N-methyl-D-aspartate (NMDA) Receptor

Gamma aminobutyric acid (GABA) Receptor

References

  1. 1.0 1.1 1.2 Huff JS, Fountain NB (2011). “Pathophysiology and definitions of seizures and status epilepticus”. Emerg Med Clin North Am. 29 (1): 1–13. doi:10.1016/j.emc.2010.08.001. PMID 21109098.
  2. Mulley JC, Scheffer IE, Petrou S, Berkovic SF (2003). “Channelopathies as a genetic cause of epilepsy”. Curr Opin Neurol. 16 (2): 171–6. doi:10.1097/01.wco.0000063767.15877.c7. PMID 12644745.
  3. Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR; et al. (1995). “A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy”. Nat Genet. 11 (2): 201–3. doi:10.1038/ng1095-201. PMID 7550350.
  4. Sutula T, Cascino G, Cavazos J, Parada I, Ramirez L (1989). “Mossy fiber synaptic reorganization in the epileptic human temporal lobe”. Ann Neurol. 26 (3): 321–30. doi:10.1002/ana.410260303. PMID 2508534.
  5. Andermann F (2000). “Cortical dysplasias and epilepsy: a review of the architectonic, clinical, and seizure patterns”. Adv Neurol. 84: 479–96. PMID 11091890.
  6. 6.0 6.1 Fountain NB, Lothman EW (1995). “Pathophysiology of status epilepticus”. J Clin Neurophysiol. 12 (4): 326–42. PMID 7560021.
  7. Stafstrom CE, Carmant L (2015). “Seizures and epilepsy: an overview for neuroscientists”. Cold Spring Harb Perspect Med. 5 (6). doi:10.1101/cshperspect.a022426. PMC 4448698. PMID 26033084.

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH